Add To Watchlist
Share URL
About The Company
Description
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom.
Read More
Overview
Value
1
Growth
53
Health
29
Management
27
Analyst Opinion
74
Total
37
All Scores Out Of 100
Best Features
- Earnings growth has improved recently
- Has a history of share buybacks
- Liked by analysts
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Income is not covering expenditure and investment
- Earnings are negative
- Has a high level of debt
- Poor overall financial health
- No margin of safety at their current market price 0
Market Peers
ORX.ST
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
-252.05%
Revenue Growth (5 Year Average)
4.85%
Ratings Consensus
Buy
Share Buybacks
0.03%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
1
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 15.3 SEK
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-38.61%
PE/Earnings Growth
N/A
Price/Book
1.76x
Growth
Growth Score
53
- ✔ Revenue growth has improved this yeara
- ✔ 5 Year Average Earnings growth of 17.19% is higher than the market average (14.48%)
- ✔ Earnings growth has improved this year
- ✔ 5 Year Average Cashflow growth of 15.39% is higher than the market average (12.35%)
- ✘ 5 Year Average Revenue growth of 4.85% is lower than the market average (10.97%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
4.85%
Earnings Growth
17.19%
Cashflow Growth
15.39%
Health
Health Score
29
Altman Z Score
0.96
Piostroski Score
2.00
Debt/Equity
1.82x
Current Assets/Liabilities
2.21x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
0.65x
Management
Management Score
27
Average Buybacks/Dilution
0.03%
Recent Buybacks/Dilution
-0.06%
5 Year Price Volitility
38.45%
Return On Assets
-2.20%
Return On Capital Employed
2.53%
Return On Equity
-8.86%
Return On Free Cashflow
-264.48%
Return On Investments
-2644.78%
Analysts
Analyst Opinion
74
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Currency
SEK
Beta
Vol Avg
Ceo
Mr. Nikolaj Sorensen
Cik
Cusip
Exchange
Stockholm Stock Exchange
Full Time Employees
Industry
Drug Manufacturers—Specialty & Generic
Sector
Healthcare
Ipo Date
Address
P.O. Box 303
City
Uppsala
State
Country
Zip
751 05
Phone
46 1 87 80 88 00
All financial data provided by FMP